Compare Garmin Ltd. (GRMN) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Garmin Ltd. vs Tenet Healthcare Corporation — how do they compare? Garmin Ltd. trades at $271.28 (market cap $53.26B), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: Garmin Ltd. is far larger — about 2.5× Tenet Healthcare Corporation's market cap, and Garmin Ltd. pays a 1.52% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Garmin Ltd. for 83 Days and Tenet Healthcare Corporation for 15 Days on average.
| GRMN | THC | |
|---|---|---|
Market Cap | $53.26B | $20.92B |
Volume | 529,054 | 455,764 |
Sector | Technology | Health |
52-Week High | $313.16 | $280.77 |
52-Week Low | $187.10 | $161.37 |
Typical Hold Time | 83 Days | 15 Days |
Enterprise Value | $50.77B | $32.00B |
Dividend Yield | 1.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Garmin (GRMN) trades at $268.44, down 3.86% on the day, amid a broader bearish technical signal. The company demonstrates strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.81 beating estimates of $2.30. Revenue growth remains robust, rising from $4.9B in 2022 to $7.25B in 2025, with net income margins above 20%. Recent positive developments include multiple product awards and new feature rollouts across marine, automotive, and fitness segments.
Garmin presents a compelling investment case with strong profitability and consistent execution, though near-term technical pressure and cautious analyst sentiment (71% hold rating) suggest potential volatility. The consensus price target of $320.25 implies 19% upside, but investors should monitor competitive pressures in the wearable tech space and macroeconomic factors affecting consumer discretionary spending.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Garmin Ltd.
Garmin produces GPS-enabled hardware and software for five verticals: fitness, outdoors, auto, aviation, and marine. The company relies on licensing mapping data to enable its hardware specialized for often niche activities like scuba diving or sailing. Garmin operates in 100 countries and sells its products via distributors as well as relationships with original equipment manufacturers.
Read more on GRMN →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
